Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN 20 versus LIPOSYN III 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN 20 versus LIPOSYN III 20.
LIPOSYN 20% vs LIPOSYN III 20%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposyn 20% is an intravenous fat emulsion providing essential fatty acids (linoleic and linolenic acids) and triglycerides. It serves as a caloric source and prevents essential fatty acid deficiency by supplying substrate for energy metabolism and cell membrane synthesis.
Liposyn III 20% is a lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories. It serves as a source of energy and prevents essential fatty acid deficiency by supplying triglycerides that are hydrolyzed to free fatty acids and glycerol for metabolism.
Intravenous infusion: 1-2 g/kg/day (as soybean oil) initially, up to 2.5 g/kg/day, not to exceed 50% of total caloric intake; infusion rate not to exceed 0.1 g/kg/hour for first 30 minutes; if no adverse reactions, may increase to 0.2 g/kg/hour.
Adults: 500 mL to 2500 mL per day via continuous intravenous infusion (including peripheral or central vein); typical rate: 0.5-1 mL/kg/h initially, increasing to 1.5-2 mL/kg/h as tolerated. Maximum infusion rate: 2.5 mL/kg/h.
None Documented
None Documented
Triglyceride clearance half-life approximately 30-60 minutes; depends on lipase activity and clinical status.
The terminal elimination half-life of infused triglycerides is approximately 0.5–1 h (33–60 min). Clearance is saturable; at high infusion rates, half-life may prolong.
Lipids are metabolized; <10% excreted renally as free fatty acids; biliary/fecal excretion minimal.
Primarily eliminated via endogenous lipid metabolic pathways (beta-oxidation in tissues). <5% excreted unchanged in urine; minimal biliary/fecal elimination.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion